FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2095793029> ?p ?o ?g. }

• W2095793029 endingPage "276" @default.
• W2095793029 startingPage "270" @default.
• W2095793029 abstract "Background The purpose of this study was to retrospectively report clinical outcomes on a consecutive series of older early breast cancer patients treated with once-weekly adjuvant whole-breast radiation therapy (WBRT) after breast-conserving surgery (BCS). Patients and Methods A total of 291 patients (298 breasts) were treated with WBRT between 2007 and 2013. Patients were given 6 to 6.5 Gy in 5 weekly fractions (total dose, 32.5-30 Gy) over 5 weeks. Clinical end points were local control (LC), disease-free (DFS), cancer-specific (CSS), and overall survival (OS), and acute and late toxicity and cosmesis. Prognostic clinical variables were assessed with respect to DFS. Results Median follow-up was 46.5 months (range, 12-84 months). The 3- and 5-year LC rates were 99.5% (95% confidence interval [CI], 96.4-99.9) and 98% (95% CI, 91.1-99.6). The 3- and 5-year CSS and OS were 97.7% (95% CI, 94.5-99.1), 95.3% (95% CI, 90.5-97.7), 94.4% (95% CI, 90.4-96.7), and 83.6% (95% CI, 76.1-88.9), respectively. Maximum detected acute skin toxicity was Grade (G) 0 in 71.8% of patients, G1 in 22.6%, G2 in 4.8%, G3 in 1%, and G4 in 0.3%. Treatment interruption occurred in 2 patients because of severe skin reactions. Late skin toxicity consisted of G1 fibrosis in 31.5% of patients, G2 in 4.2%, and G3 in 3.5%. Grade 1 edema was observed in 7% of patients, G2 in 4.2%, and G3 in 1.4%. G1 telangiectasia occurred in 1.8% and G3 in 0.7%. G1 hyperpigmentation was found in 4.6% of patients, G2 in 2.4%, and G1 atrophy was detected in 2.1%. Pain was observed as G1 in 13%, G2 in 1.8%, and G3 in 0.4%. Cosmetic results were good to excellent in 86.4% and fair to poor in 13.6%. Conclusion Once-weekly hypofractionated WBRT (30-32-5 Gy in 5 fractions), delivered with standard tangential fields with the patient in the supine position seems feasible and effective for a selected population of primarily old breast cancer patients with predominantly low-risk features. This schedule might allow fragile patients to receive adjuvant WBRT after BCS, increasing radiotherapy accessibility and utilization." @default.
• W2095793029 created "2016-06-24" @default.
• W2095793029 creator A5011436647 @default.
• W2095793029 creator A5016935270 @default.
• W2095793029 creator A5018591118 @default.
• W2095793029 creator A5019407140 @default.
• W2095793029 creator A5045918003 @default.
• W2095793029 creator A5053722886 @default.
• W2095793029 creator A5060509370 @default.
• W2095793029 creator A5061193350 @default.
• W2095793029 creator A5070688729 @default.
• W2095793029 creator A5072049068 @default.
• W2095793029 creator A5073276891 @default.
• W2095793029 date "2015-08-01" @default.
• W2095793029 modified "2023-09-27" @default.
• W2095793029 title "Once-Weekly Hypofractionated Whole-Breast Radiotherapy After Breast-Conserving Surgery in Older Patients: A Potential Alternative Treatment Schedule to Daily 3-Week Hypofractionation" @default.
• W2095793029 cites W103989194 @default.
• W2095793029 cites W1728715977 @default.
• W2095793029 cites W1830334259 @default.
• W2095793029 cites W197523496 @default.
• W2095793029 cites W1983351193 @default.
• W2095793029 cites W1991117132 @default.
• W2095793029 cites W1996375113 @default.
• W2095793029 cites W1997274671 @default.
• W2095793029 cites W2002182224 @default.
• W2095793029 cites W2019540691 @default.
• W2095793029 cites W2024605012 @default.
• W2095793029 cites W2030822657 @default.
• W2095793029 cites W2041428167 @default.
• W2095793029 cites W2043945205 @default.
• W2095793029 cites W2053860026 @default.
• W2095793029 cites W2059243286 @default.
• W2095793029 cites W2076283794 @default.
• W2095793029 cites W2076782662 @default.
• W2095793029 cites W2082643186 @default.
• W2095793029 cites W2088511345 @default.
• W2095793029 cites W2088882392 @default.
• W2095793029 cites W2088908824 @default.
• W2095793029 cites W2092617165 @default.
• W2095793029 cites W2096499183 @default.
• W2095793029 cites W2097656464 @default.
• W2095793029 cites W2103608035 @default.
• W2095793029 cites W2109454278 @default.
• W2095793029 cites W2110583155 @default.
• W2095793029 cites W2120055024 @default.
• W2095793029 cites W2120560566 @default.
• W2095793029 cites W2122428334 @default.
• W2095793029 cites W2134356947 @default.
• W2095793029 cites W2137730526 @default.
• W2095793029 cites W2139510434 @default.
• W2095793029 cites W2143899676 @default.
• W2095793029 cites W2155220817 @default.
• W2095793029 cites W2158615473 @default.
• W2095793029 cites W2163533947 @default.
• W2095793029 cites W2166112765 @default.
• W2095793029 cites W3021410191 @default.
• W2095793029 doi "https://doi.org/10.1016/j.clbc.2014.12.011" @default.
• W2095793029 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25666079" @default.
• W2095793029 hasPublicationYear "2015" @default.
• W2095793029 type Work @default.
• W2095793029 sameAs 2095793029 @default.
• W2095793029 citedByCount "31" @default.
• W2095793029 countsByYear W20957930292015 @default.
• W2095793029 countsByYear W20957930292016 @default.
• W2095793029 countsByYear W20957930292017 @default.
• W2095793029 countsByYear W20957930292018 @default.
• W2095793029 countsByYear W20957930292019 @default.
• W2095793029 countsByYear W20957930292020 @default.
• W2095793029 countsByYear W20957930292021 @default.
• W2095793029 countsByYear W20957930292022 @default.
• W2095793029 countsByYear W20957930292023 @default.
• W2095793029 crossrefType "journal-article" @default.
• W2095793029 hasAuthorship W2095793029A5011436647 @default.
• W2095793029 hasAuthorship W2095793029A5016935270 @default.
• W2095793029 hasAuthorship W2095793029A5018591118 @default.
• W2095793029 hasAuthorship W2095793029A5019407140 @default.
• W2095793029 hasAuthorship W2095793029A5045918003 @default.
• W2095793029 hasAuthorship W2095793029A5053722886 @default.
• W2095793029 hasAuthorship W2095793029A5060509370 @default.
• W2095793029 hasAuthorship W2095793029A5061193350 @default.
• W2095793029 hasAuthorship W2095793029A5070688729 @default.
• W2095793029 hasAuthorship W2095793029A5072049068 @default.
• W2095793029 hasAuthorship W2095793029A5073276891 @default.
• W2095793029 hasConcept C121608353 @default.
• W2095793029 hasConcept C126322002 @default.
• W2095793029 hasConcept C141071460 @default.
• W2095793029 hasConcept C2777757722 @default.
• W2095793029 hasConcept C2780943399 @default.
• W2095793029 hasConcept C2781467025 @default.
• W2095793029 hasConcept C29730261 @default.
• W2095793029 hasConcept C44249647 @default.
• W2095793029 hasConcept C509974204 @default.
• W2095793029 hasConcept C530470458 @default.
• W2095793029 hasConcept C71924100 @default.
• W2095793029 hasConceptScore W2095793029C121608353 @default.
• W2095793029 hasConceptScore W2095793029C126322002 @default.
• W2095793029 hasConceptScore W2095793029C141071460 @default.
• W2095793029 hasConceptScore W2095793029C2777757722 @default.

• next